Latest Capital Raises News

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

Sarama Resources has completed the acquisition of an 80% stake in the Mt Venn Gold Project, boosting its Laverton landholding to 1,000km² across two major projects. The move positions Sarama to explore promising gold and base metal targets in a prolific Australian gold district.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Alligator Energy reports a 10% increase in indicated uranium resources at its Samphire Project, secures a $17.25 million capital raise, and announces a CEO transition as it advances key uranium exploration and development milestones.

QPM Energy has successfully raised $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $2 million target to accelerate key gas power projects in Queensland.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Canterbury Resources advances its flagship Briggs Copper Project with a near-complete scoping study and imminent deep drilling, while expanding exploration across Queensland and Papua New Guinea.

Lake Resources reports a significant 40% reduction in quarterly cash expenditures alongside a 10% increase in lithium resources at its flagship Kachi project, while advancing key development milestones and exploring strategic options.

Breakthrough Minerals has completed its acquisition of the high-grade Errolls Gold Project in Western Australia and raised A$1.2 million to fund an imminent drilling campaign targeting promising gold lodes.